<html>
<head>
<title>Form 8-K
</title>
</head>
<body>




<hr size=3 noshade>

<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>UNITED STATES<br>
SECURITIES AND EXCHANGE COMMISSION<br></b></font>
<font face="Times New Roman, Times, Serif" size=2>Washington, DC 20549</font>
</p>

<hr width=25% noshade>

<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>FORM 8-K<br>
<br></b></font></p>
<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>CURRENT REPORT</b></font><br><font face="Times New Roman, Times, Serif" size=2><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934<br></b></font></p>
<p align=center>
<font face="Times New Roman, Times, Serif" size=2>Date of Report&nbsp;&nbsp;(Date of earliest event reported):&nbsp;&nbsp;&nbsp;&nbsp;February 1, 2006</font><br></p>
<hr width=25% noshade>
<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>MILLENNIUM PHARMACEUTICALS, INC.</b></font><br><font face="Times New Roman, Times, Serif" size=2>(Exact name of registrant as specified in its charter)</font></p>
<table width=100% border=0 cellpadding=0 cellspacing=0 align=center>

<tr>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2><b>Delaware</b></font></td>
<td width=34% align=center valign=top><font face="Times New Roman, Times, Serif" size=2><b>0-28494</b></font></td>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2><b>04-3177038</b></font></td>
</tr>
<tr>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2>(State or other jurisdiction<br>of incorporation)</font></td>
<td width=34% align=center valign=top><font face="Times New Roman, Times, Serif" size=2>(Commission file number)</font></td>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2>(IRS&nbsp;Employer<br>Identification&nbsp;No.)</font></td>
</tr>




</table>


<p align=center><font face="Times New Roman, Times, Serif" size=2><b>40 Landsdowne Street<br>Cambridge, Massachusetts 02139</b><br>
(Address of principal executive offices)&nbsp;(zip code)</font></p>

<p align=center><font face="Times New Roman, Times, Serif" size=2><b>(617)&nbsp;&nbsp;679-7000<br></b>
(Registrant's telephone number, including area code)</font></p>

<p align=center><font face="Times New Roman, Times, Serif" size=2><b>Not applicable<br></b>
(Former name or former address if changed since last report)</font></p>

<p align=left><font face="Times New Roman, Times, Serif" size=2>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></p>

<table width=100% border=0 cellpadding=0 cellspacing=0>

<tr>
<td align=right valign=top width=3%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top width=1%><font face="Times New Roman, Times, Serif" size=2>&#144;</font></td>
<td align=right valign=top width=2%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=top width=94%><font face="Times New Roman, Times, Serif" size=2>Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&#144;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&#144;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td></tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&#144;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</font></td></tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>

</table>




<hr size=3 noshade width=100%>

<p align=left><font face="Times New Roman, Times, Serif" size=2><b>Item 1.01&nbsp;&nbsp;&nbsp;&nbsp;Entry into a Material Definitive Agreement.</b></font></p>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On February 2, 2006, the Board of
Directors of Millennium Pharmaceuticals, Inc. (the &#147;Company&#148;) approved the 2006
priority goals for the Company&#146;s Success Sharing Bonus Program. The goals include:
growing sales of VELCADE&reg; (bortezomib) for Injection by a specified dollar amount;
advancing the Company&#146;s high-priority clinical molecules according to plan; advancing
a specified number of target candidates to development candidate status; and managing the
Company&#146;s business to achieve specified financial results. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>A summary of the Success Sharing
Bonus Program is attached as an exhibit to this Current Report on Form 8-K and is
incorporated herein by reference. </FONT></P>



<p align=left><font face="Times New Roman, Times, Serif" size=2><b>Item 5.02&nbsp;&nbsp;&nbsp;&nbsp;Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
</b></font></p>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On February 1, 2006, the
Company&#146;s Board of Directors elected Anthony H. Wild to serve as a Class III member
of the Board of Directors of the Company for a term beginning on February 3, 2006 through
the date of the 2008 Annual Meeting of Stockholders when the Class III directors&#146;
terms expire. Dr. Wild was also elected to serve on the Audit Committee and the Research
and Development Committee of the Board of Directors. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Flush" FSL="Default" -->
     <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Dr. Wild is Chairman and Chief Executive Officer of MedPointe Pharmaceuticals, a
          privately held pharmaceutical company specializing in respiratory, allergy,
          central nervous system, cough-cold and pediatric products. He has approximately
          30 years of experience in the global pharmaceutical industry. Prior to joining
          MedPointe, he served as Executive Vice President of Warner-Lambert and President
          of its Pharmaceutical Sector (until the company merged with Pfizer in 2000) with
          worldwide responsibility for Warner-Lambert&#146;s pharmaceutical commercial
          operations and research and development. Prior to that he spent 22 years with
          Schering-Plough Corporation&#146;s operations in six countries and began his
          career as a development chemist for Sandoz AG in Switzerland. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Flush" FSL="Default" -->
     <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Dr. Wild is a member of the Board of Advisors to the Joseph L. Mailman School of
          Public Health at Columbia University, a Trustee of the Healthcare Institute of
          New Jersey, past Chairman of the International Section of Pharmaceutical
          Research and Manufacturers of America, and past Governor of the American Chamber
          of Commerce in Japan. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Flush" FSL="Default" -->
     <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Dr. Wild graduated from the University of York with a B.A. honors degree in
          Chemistry and received a Ph.D. in Physical Chemistry from the University of
          Cambridge (Churchill College), both in the U.K. </FONT></P>




<p align=left><font face="Times New Roman, Times, Serif" size=2><b>Item&nbsp;&nbsp;&nbsp;&nbsp;9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial
Statements and Exhibits.</b></font></p>

<table border=0 cellpadding=0 cellspacing=0>
<tr>
<td align=left width=20%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left width=10%><font face="Times New Roman, Times, Serif" size=2>(c)</font></td>
<td align=left width=70%><font face="Times New Roman, Times, Serif" size=2>Exhibits</font></td>
</tr>
<tr>
<td align=left width=20%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=10%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left width=70%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td width=20%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=10%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=70%><font face="Times New Roman, Times, Serif" size=2>See Exhibit Index attached to this Current Report on Form 8-K.</font></td>
</tr>
<tr>
<td align=left width=20%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=10%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left width=70%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>

</table>


<p align=center><font face="Times New Roman, Times, Serif" size=2>2</font></p>
<hr size=3 noshade>




<p align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2><b><a name="sig">SIGNATURE</a></b></font></p>

<p><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.</font></p>




<table border=0 cellpadding=0 cellspacing=0>
<tr valign=bottom>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td colspan=2><font face="Times New Roman, Times, Serif" size=2>MILLENNIUM PHARMACEUTICALS, INC.<br>(Registrant)<br><br></font></td>
</tr>
<tr valign=bottom>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date: February 6, 2006&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>By&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2>/s/&nbsp;&nbsp;MARSHA H. FANUCCI</font></td>
</tr>
<tr valign=top>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2></font><hr noshade></td>
</tr>
<tr valign=top>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2>Marsha H. Fanucci</font></td>
</tr>
<tr valign=top>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2>Senior Vice President and Chief Financial Officer</font></td>
</tr>
</table>




<p align=center><font face="Times New Roman, Times, Serif" size=2>3</font></p>
<hr noshade size=3>



<p><font face="Times New Roman, Times, Serif" size=2><b><a name="index">EXHIBIT INDEX</a></b></font></p>

<table border=0 cellpadding=0 cellspacing=0>
<tr valign=bottom>
<th width=9% align=center colspan=2><font face="Times New Roman, Times, Serif" size=2>Exhibit No.<br></font><hr noshade></th>
<th width=3%>&nbsp;</th>
<th width=68% align=center><font face="Times New Roman, Times, Serif" size=2>Description<br></font><hr noshade></th>
<th width=20% align=left><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></th>
</tr>
<tr valign=top>
<td width=3%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=6%><font face="Times New Roman, Times, Serif" size=2>10.1</font></td>
<td width=3%>&nbsp;</td>
<td width=68% align=left><font face="Times New Roman, Times, Serif" size=2>Description of Success Sharing Bonus Program of Millennium Pharmaceuticals, Inc.
</font></td>
<td width=20% align=left><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>

</table>




<p align=center><font face="Times New Roman, Times, Serif" size=2>4</font></p>
<hr noshade size=3>

























</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "fm8k02062006.htm", "description": "FORM 8-K", "secsgml_size_bytes": 15341}]
{"company-data": {"conformed-name": "MILLENNIUM PHARMACEUTICALS INC", "cik": "0001002637", "assigned-sic": "2834", "irs-number": "043177038", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-28494", "film-number": "06580853"}, "business-address": {"street1": "40 LANDSDOWNE STREET", "city": "CAMBRIDGE", "state": "MA", "zip": "02139", "phone": "6176797000"}, "mail-address": {"street1": "40 LANDSDOWNE STREET", "city": "CAMBRIDGE", "state": "MA", "zip": "02139"}}
Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report  (Date of earliest event reported):    February 1, 2006
MILLENNIUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
0-28494
04-3177038
(State or other jurisdiction
of incorporation)
(Commission file number)
(IRS Employer
Identification No.)
40 Landsdowne Street
Cambridge, Massachusetts 02139
(Address of principal executive offices) (zip code)
(617)  679-7000
(Registrant's telephone number, including area code)
Not applicable
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01    Entry into a Material Definitive Agreement.
On February 2, 2006, the Board of
Directors of Millennium Pharmaceuticals, Inc. (the "Company") approved the 2006
priority goals for the Company's Success Sharing Bonus Program. The goals include:
growing sales of VELCADE® (bortezomib) for Injection by a specified dollar amount;
advancing the Company's high-priority clinical molecules according to plan; advancing
a specified number of target candidates to development candidate status; and managing the
Company's business to achieve specified financial results.
A summary of the Success Sharing
Bonus Program is attached as an exhibit to this Current Report on Form 8-K and is
incorporated herein by reference.
Item 5.02    Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On February 1, 2006, the
Company's Board of Directors elected Anthony H. Wild to serve as a Class III member
of the Board of Directors of the Company for a term beginning on February 3, 2006 through
the date of the 2008 Annual Meeting of Stockholders when the Class III directors'
terms expire. Dr. Wild was also elected to serve on the Audit Committee and the Research
and Development Committee of the Board of Directors.
Dr. Wild is Chairman and Chief Executive Officer of MedPointe Pharmaceuticals, a
          privately held pharmaceutical company specializing in respiratory, allergy,
          central nervous system, cough-cold and pediatric products. He has approximately
          30 years of experience in the global pharmaceutical industry. Prior to joining
          MedPointe, he served as Executive Vice President of Warner-Lambert and President
          of its Pharmaceutical Sector (until the company merged with Pfizer in 2000) with
          worldwide responsibility for Warner-Lambert's pharmaceutical commercial
          operations and research and development. Prior to that he spent 22 years with
          Schering-Plough Corporation's operations in six countries and began his
          career as a development chemist for Sandoz AG in Switzerland.
Dr. Wild is a member of the Board of Advisors to the Joseph L. Mailman School of
          Public Health at Columbia University, a Trustee of the Healthcare Institute of
          New Jersey, past Chairman of the International Section of Pharmaceutical
          Research and Manufacturers of America, and past Governor of the American Chamber
          of Commerce in Japan.
Dr. Wild graduated from the University of York with a B.A. honors degree in
          Chemistry and received a Ph.D. in Physical Chemistry from the University of
          Cambridge (Churchill College), both in the U.K.
Item    9.01    Financial
Statements and Exhibits.
(c)
Exhibits
See Exhibit Index attached to this Current Report on Form 8-K.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
MILLENNIUM PHARMACEUTICALS, INC.
(Registrant)
Date: February 6, 2006
By
/s/  MARSHA H. FANUCCI
Marsha H. Fanucci
Senior Vice President and Chief Financial Officer
3
EXHIBIT INDEX
Exhibit No.
Description
10.1
Description of Success Sharing Bonus Program of Millennium Pharmaceuticals, Inc.
4